Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Net Margin (2018 - 2025)

Historic Net Margin for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to 9.79%.

  • 10x Genomics' Net Margin rose 199200.0% to 9.79% in Q4 2025 from the same period last year, while for Dec 2025 it was 6.77%, marking a year-over-year increase of 231300.0%. This contributed to the annual value of 6.77% for FY2025, which is 231300.0% up from last year.
  • Latest data reveals that 10x Genomics reported Net Margin of 9.79% as of Q4 2025, which was up 199200.0% from 18.44% recorded in Q3 2025.
  • 10x Genomics' 5-year Net Margin high stood at 19.97% for Q2 2025, and its period low was 60.52% during Q3 2023.
  • For the 5-year period, 10x Genomics' Net Margin averaged around 25.09%, with its median value being 24.16% (2024).
  • Its Net Margin has fluctuated over the past 5 years, first skyrocketed by 3575100bps in 2021, then crashed by -467000bps in 2022.
  • Quarter analysis of 5 years shows 10x Genomics' Net Margin stood at 12.85% in 2021, then grew by 14bps to 11.02% in 2022, then tumbled by -141bps to 26.61% in 2023, then fell by -12bps to 29.71% in 2024, then soared by 67bps to 9.79% in 2025.
  • Its Net Margin stands at 9.79% for Q4 2025, versus 18.44% for Q3 2025 and 19.97% for Q2 2025.